首页> 外文期刊>Journal of proteome research >Functional classification of cellular proteome profiles support the identification of drug resistance signatures in melanoma cells
【24h】

Functional classification of cellular proteome profiles support the identification of drug resistance signatures in melanoma cells

机译:细胞蛋白质组图谱的功能分类支持黑色素瘤细胞中药物耐药性特征的鉴定

获取原文
获取原文并翻译 | 示例
           

摘要

Drug resistance is a major obstacle in melanoma treatment. Recognition of specific resistance patterns, the understanding of the patho-physiology of drug resistance, and identification of remaining options for individual melanoma treatment would greatly improve therapeutic success. We performed mass spectrometry-based proteome profiling of A375 melanoma cells and HeLa cells characterized as sensitive to cisplatin in comparison to cisplatin resistant M24met and TMFI melanoma cells. Cells were fractionated into cytoplasm, nuclei and secretome and the proteome profiles classified according to Gene Ontology. The cisplatin resistant cells displayed increased expression of lysosomal as well as Ca~(2+) ion binding and cell adherence proteins. These findings were confirmed using Lysotracker Red staining and cell adhesion assays with a panel of extracellular matrix proteins. To discriminate specific survival proteins, we selected constitutively expressed proteins of resistant M24met cells which were found expressed upon challenging the sensitive A375 cells. Using the CPL/MUW proteome database, the selected lysosomal, cell adherence and survival proteins apparently specifying resistant cells were narrowed down to 47 proteins representing a potential resistance signature. These were tested against our proteomics database comprising more than 200 different cell types/cell states for its predictive power. We provide evidence that this signature enables the automated assignment of resistance features as readout from proteome profiles of any human cell type. Proteome profiling and bioinformatic processing may thus support the understanding of drug resistance mechanism, eventually guiding patient tailored therapy.
机译:耐药性是黑色素瘤治疗的主要障碍。识别特定的抗药性模式,了解药物抗药性的病理生理学以及确定单个黑素瘤治疗的剩余选择将大大提高治疗成功率。与基于顺铂耐药的M24met和TMFI黑色素瘤细胞相比,我们对A375黑色素瘤细胞和表征为对顺铂敏感的HeLa细胞进行了基于质谱的蛋白质组分析。将细胞分为细胞质,细胞核和分泌组,并根据基因本体论对蛋白质组进行分类。顺铂耐药细胞显示溶酶体以及Ca〜(2+)离子结合和细胞粘附蛋白的表达增加。使用Lysotracker Red染色和一组细胞外基质蛋白的细胞粘附测定法证实了这些发现。为了区分特定的生存蛋白,我们选择了抗性M24met细胞的组成型表达蛋白,这些蛋白在挑战敏感的A375细胞后即可表达。使用CPL / MUW蛋白质组数据库,将选择的溶酶体,细胞粘附和存活蛋白明显指定为抗性细胞,缩小到47种代表潜在抗性标记的蛋白。针对我们的蛋白质组学数据库,对这些蛋白质进行了测试,该数据库包含200多种不同的细胞类型/细胞状态,具有预测能力。我们提供的证据表明,该签名能够自动从任何人类细胞类型的蛋白质组图谱中读出抗性特征。因此,蛋白质组分析和生物信息学处理可以支持对耐药机制的了解,最终指导患者量身定制的治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号